Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-60

I just gave you one where SI claimed the only thing left to discuss with the FDA was the specifics of labelling. What about the one where he "didn't know why" Novartis walked away (even though the lawyers must have pointed it out specifically in the letter they sent withdrawing from the contract). Novartis were supposed to ratify the contract within weeks... The claim that the Covid trial was "completed" even though it was stopped before full enrolment because it failed a futility test. Every blinded controlled trial has failed to achieve the primary end point but was represented to investors as a "success" because one of many secondary end points achieved statistical significance (providing they were not adjusted for multiplicity). The never ending deep discussions with major partners. The "collegial" relationship with the FDA. The supposedly "validated" potency assay. The list just goes on and on and on....